FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
14 mars 2024 17h18 HE
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
05 janv. 2023 09h00 HE
|
Clearmind Medicine Inc.
In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity Tel Aviv, Israel /...
NASH kNOWledge Adds David Garcia, PhD as New Board Member
13 sept. 2022 09h00 HE
|
NASH kNOWledge
PITTSBURGH, Sept. 13, 2022 (GLOBE NEWSWIRE) -- As NASH kNOWledge celebrates its fourth year helping to spread education and awareness about nonalcoholic fatty liver disease, it has a couple of...
NASH kNOWledge Launches Spanish Language Website to Address Community Need for Those at Risk for Nonalcoholic Liver Disease
28 juin 2022 09h00 HE
|
NASH EDUCATION
PITTSBURGH, June 28, 2022 (GLOBE NEWSWIRE) -- NASH kNOWledge today announced the launch of HigadoGraso.org, a new Spanish language website that provides information for those at-risk for...
Global non-alcoholic fatty liver disease & NASH market is projected to reach at a market value of US$62.06 Billion by 2031: Visiongain Research Inc
12 avr. 2022 10h35 HE
|
Visiongain Ltd
Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast 2021-2031: - By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity, Other Disease Causes) By...
Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization
07 déc. 2021 10h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M...
Velacur™ Data Presented at 2021 AASLD The Liver Meeting®
12 nov. 2021 08h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health...
Sonic Incytes Showcases Velacur™ at ACG 2021
13 oct. 2021 10h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld...
Sonic Incytes Announces FDA Clearance and US Launch of Velacur™ to Help Manage Emerging Health Crisis
20 oct. 2020 10h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver...
National Lipid Association Announces Recipients of 2018-19 Junior Faculty Research Awards
06 juil. 2018 13h00 HE
|
National Lipid Association
JACKSONVILLE, Fla., July 06, 2018 (GLOBE NEWSWIRE) -- The National Lipid Association announced on Friday the recipients of its 2018-19 Junior Faculty Research Awards for Clinical Science and Basic...